Tear Film Innovations, Exicure, Genisphere Complete Financing Rounds

November 10, 2017: By Jon Swedien


Tear Film Completes $9 Series A Round

Tear Film Innovations announced Nov. 7 it completed a $9 million Series A preferred stock funding round.

The San Diego company’s flagship product, the iLux system, is an investigational device for dry eye and is under US FDA review.

The device enables eye care professionals to provide in-office treatment of blocked meibomian glands through targeted heating and compression of affected eyelids. TFI recently completed a multi-site clinical study to demonstrate the safety and efficacy of the system.

Visionary Ventures Fund and Tigris Ventures led the financing round.

exicure-logoExicure Raises $31.4 Million in Private Financing

Exicure has raised about $31.4 million in private financing, the company announced Nov. 6.

The Skokie, Illinois, company is focused on creating drug treatments using three-dimensional spherical nucleic acid constructs. Exicure is pursuing an ophthalmic target candidate but has not disclosed the indication it is seeking. The ophthalmic target candidate would be delivered to the retina via an eye drop.

Exicure is also pursuing chronic conditions and orphan diseases in dermatology, respiratory and gastric disorders, and solid tumors.

In the initial private placement announced in September, Exicure raised approximately $20.1 million. Exicure raised more than $11.2 million in a subsequent financing, for a total of about $31.4 million.

download (2)Genisphere Completes $7 Million Capital Raise

Genisphere has completed a $7 million capital raise, the Hatfield, Pennsylvania, company announced Nov. 1

Genisphere is advancing its 3DNA nanotechnology platform for targeted drug delivery, and its product pipeline includes GL-249, a proposed preventive treatment for posterior capsule opacification (PCO).

PCO is a vision impairing disease that occurs in some adults and in most children following cataract surgery. PCO arises when myofibroblast cells grow in the capsule surrounding the surgical site and form cloudy scar tissue inside the eye that blocks vision. While PCO is treated readily by laser therapy, the procedure is neither risk free nor available in the developing world, Genisphere said.

Genisphere said the money it raised will be used to advance its 3DNA nanotechnology and to serve other corporate purposes.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023